These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice. Klenotich SJ; Seiglie MP; McMurray MS; Roitman JD; Le Grange D; Dugad P; Dulawa SC Neuropsychopharmacology; 2012 Jun; 37(7):1620-31. PubMed ID: 22395732 [TBL] [Abstract][Full Text] [Related]
3. Treatment with 8-OH-DPAT attenuates the weight loss associated with activity-based anorexia in female rats. Atchley DP; Eckel LA Pharmacol Biochem Behav; 2006 Apr; 83(4):547-53. PubMed ID: 16643997 [TBL] [Abstract][Full Text] [Related]
4. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Gyertyán I; Sághy K; Laszy J; Elekes O; Kedves R; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Agai Csongor E; Domány G; Kiss B; Szombathelyi Z Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):529-39. PubMed ID: 18548231 [TBL] [Abstract][Full Text] [Related]
5. Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa. Verhagen LA; Luijendijk MC; Hillebrand JJ; Adan RA Eur Neuropsychopharmacol; 2009 Mar; 19(3):153-60. PubMed ID: 18977121 [TBL] [Abstract][Full Text] [Related]
6. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15. Kiss B; Laszlovszky I; Horváth A; Némethy Z; Schmidt E; Bugovics G; Fazekas K; Gyertyán I; Agai-Csongor E; Domány G; Szombathelyi Z Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):515-28. PubMed ID: 18551280 [TBL] [Abstract][Full Text] [Related]
7. Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa? Hillebrand JJ; van Elburg AA; Kas MJ; van Engeland H; Adan RA Biol Psychiatry; 2005 Oct; 58(8):651-7. PubMed ID: 16018979 [TBL] [Abstract][Full Text] [Related]
8. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302 [TBL] [Abstract][Full Text] [Related]
9. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184 [TBL] [Abstract][Full Text] [Related]
10. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Leucht S Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080 [TBL] [Abstract][Full Text] [Related]
11. Dopamine D2 receptor overexpression in the nucleus accumbens core induces robust weight loss during scheduled fasting selectively in female mice. Welch AC; Zhang J; Lyu J; McMurray MS; Javitch JA; Kellendonk C; Dulawa SC Mol Psychiatry; 2021 Aug; 26(8):3765-3777. PubMed ID: 31863019 [TBL] [Abstract][Full Text] [Related]
12. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range. Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930 [TBL] [Abstract][Full Text] [Related]
13. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185 [TBL] [Abstract][Full Text] [Related]
14. Leptin treatment in activity-based anorexia. Hillebrand JJ; Koeners MP; de Rijke CE; Kas MJ; Adan RA Biol Psychiatry; 2005 Jul; 58(2):165-71. PubMed ID: 16038687 [TBL] [Abstract][Full Text] [Related]
15. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade. Viaro R; Marti M; Morari M Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926 [TBL] [Abstract][Full Text] [Related]
16. Examining dopamine D3 receptor occupancy by antipsychotic drugs via [3H]7-OH-DPAT ex vivo autoradiography and its cross-validation via c-fos immunohistochemistry in the rat brain. Davoodi N; te Riele P; Langlois X Eur J Pharmacol; 2014 Oct; 740():669-75. PubMed ID: 24967534 [TBL] [Abstract][Full Text] [Related]
17. Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine. Quednow BB; Wagner M; Westheide J; Beckmann K; Bliesener N; Maier W; Kühn KU Biol Psychiatry; 2006 Mar; 59(6):536-45. PubMed ID: 16139819 [TBL] [Abstract][Full Text] [Related]
18. Timing matters: The contribution of running during different periods of the light/dark cycle to susceptibility to activity-based anorexia in rats. Aston SA; Caffo BS; Bhasin H; Moran TH; Tamashiro KL Physiol Behav; 2023 Nov; 271():114349. PubMed ID: 37709000 [TBL] [Abstract][Full Text] [Related]